EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling the impact of peptides known as 'Tregitopes ...

followed by the development of N91/309 and N104/322 preferentially targeting monoclonal antibody manifesting enhanced antitumor immunity. Beyond exhaustion, CD8 + T cells can adopt various ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E-targeting antibody-drug conjugate incorporating our ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate ...

Visit https://www.apbioinc.com/en/ for more information about AP Biosciences and its pipeline of next-generation cancer therapies.

“Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E ...